News
Otsuka’s Lupkynis receives NICE green light
Otsuka Pharmaceuticals has revealed that the National Institute for Health and Care Excellence (NICE) has recommended Lupkynis in combination with mycophenolate mofetil (MMF).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Otsuka Pharmaceuticals has revealed that the National Institute for Health and Care Excellence (NICE) has recommended Lupkynis in combination with mycophenolate mofetil (MMF).